Krystal Biotech (KRYS) Stock Price, Quote, News & History | Benzinga

SPY770.73+0.22%QQQ722.85+0.73%BTC/USD82,673.44−0.32%DIA524.31−0.01%GLD377.24−0.11%TLT79.93−0.25%

Krystal Biotech Inc (KRYS) Stock Price, Quote, News & History

KRYSNASDAQ

Trade with Public

Trade with Public

$325.42

5.171.61%

Last update: Oct 20, 4:00 PM

$325.42

5.171.61%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$321.80

Close

$325.42

Volume / Avg.

195.45K / 365.91K

Day Range

$321.26 - $328.76

52 Wk Range

183.03 - 382.54

Market Cap

$9.51B

P/E Ratio

40.14

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

19.79%

Days to Cover

11.19

Recent Krystal Biotech, Inc. News

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.

Vandana Singh

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.

Avi Kapoor

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Namrata Sen

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data.

Vandana Singh

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

272.34M

Investing Cash Flow (TTM)

-218.29M

Financing Cash Flow (TTM)

23.97M

Free Cash Flow (TTM)

257.78M

Capital Expenditure (TTM)

-14.56M

Net Change in Cash (TTM)

78.02M

Analyst Trends and Forecast

1

Jul

2

Aug

2

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$8.64B

PE Ratio (TTM)

40.14

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

22.06

PB Ratio (TTM)

6.98

Earnings Yield % (TTM)

2.49%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

42.28

Price / EBITDA (TTM)

47.53

Price / Free Cash Flow (TTM)

37.69

Book Value / Share

$45.92

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$427.74M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-